UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 6, 2010
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
January 5,
2010, Oramed Pharmaceuticals Inc. issued a press release announcing that its
Chief Excutive Officer, Nadav Kidron, will present at the 2010 OneMedPlace
Finance Forum which will take place at The Sir Francis Drake Hotel in
San Francisco California. Nadav Kidron is scheduled to speak on January 13, 2010
at 11:00 AM PST in the Cyprus Room on the second floor. He will discuss the
company's strategic initiatives, company updates and Oramed’s product
pipeline.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
Exhibit
Number
|
Description
|
|
|
|
|
99.1
|
Press
Release dated January 5, 2010.
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORAMED PHARMACEUTICALS
INC.
|
Dated:
January 6, 2010
|
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
Nadav
Kidron
|
|
|
|
President,
CEO and
Director
|
Exhibit
Index
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated January 5,
2010.
|